Drug Approvals

How can the industry balance the need for faster drug approvals with the necessity of ensuring patient safety and efficacy?

Pharma's Almanac

Advocacy

From Patients to Partners: The Rising Power of Advocacy in Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

Biomarkers

The Biomarker Revolution in Medicine and Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

HTS

The High-Throughput Screening Transformation in Modern Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

Accelerated Approval

30 Years of Accelerated Approvals: Fast-Tracking Innovation in Drug Development

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Structural Biology

The Disruptive Impact of Structural Biology on Biopharmaceutical Innovation

David Alvaro, Ph.D.

Pharma's Almanac

Real-World Evidence

Overcoming Challenges and Unlocking the Potential of Real-World Evidence

David Alvaro, Ph.D.

Pharma's Almanac

Cannabinoids

Unlocking New Frontiers with Cannabinoid and Psychedelic Therapies

David Alvaro, Ph.D.

Pharma's Almanac

Biosimilars

Biosimilars Through the Years: Transforming Access and Cost in Biologics

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Small Biotechs

Five Small Biotechs to Watch: March 2025

David Alvaro, Ph.D.

Pharma's Almanac

Radioconjugates

Rising Interest in Radioconjugate Therapies

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Biotechs

Five Small Biotechs to Watch: February 2025

David Alvaro, Ph.D.

Pharma's Almanac

Bbiotherapeutics

Protein Science and the Future of Biotherapeutics

Mathias Uhlén, Ph.D.

NorthX Biologics

Autoimmune Diseases

Why Autoimmune Diseases Are Taking Center Stage: Rising Prevalence, Breakthroughs, and Market Opportunities

Chia Chia Sun; Gardiner Smith

Fab Biopharma

LBPs

Exploring the Microbiome with Servatus

Servatus

Chemotherapy

Modernizing Dated Approaches to Oncology Care

FivepHusion

Antibodies

Reshaping the Approach to Therapeutic Development with i-Bodies

AdAlta

Oncology

Celebrating a Decade of Oncology Innovation at ONJ

Olivia Newton-John Cancer Research Institute

Bispecifics

Revolutionizing Autoimmune Disease Management with Soluble Bispecific Receptors

Gardiner Smith; Reiner Gentz, Ph.D.

Fab Biopharma